Nuclea Energy of Mississauga, Ont., is acquiring 89 current and pending patents from Moltex Energy, whose British parent went into administration last year. The price wasn’t disclosed, but in an April filing for a public share offering it later aborted, Nuclea said it expected to pay about $11.5 million for Moltex’s IP. (The Logic)

Talking point: A key selling point of Moltex’s technology is that it can get further energy out of waste from large conventional reactors. With more than $96 million in investment behind the effort (much of it from Canadian governments), Moltex had been working on a first deployment at New Brunswick’s Point Lepreau nuclear plant, though that’s still a long way away from fruition. Nuclea has been developing its own much smaller microreactor; CEO Josef Freundorfer said the Moltex assets expand Nuclea’s potential. It’s now pursuing a U.S. stock listing via a merger with Mangoceuticals, which sells erectile dysfunction, baldness and hormone treatments online. 

Sponsored Content

The real-world economic offshoots of sovereign AI

By Deborah Aarts

Increasing healthcare access across Canada

By Deborah Aarts

What it takes to lead a frontier firm

By Deborah Aarts

Paid promotional content